ALX Oncology Holdings, Inc. (ALXO) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

147.67 k

Shareholding (Mar 2025)

FII

5.56%

Held by 61 FIIs

DII

40.64%

Held by 28 DIIs

Promoter

31.70%

How big is ALX Oncology Holdings, Inc.?

22-Jun-2025

As of Jun 18, ALX Oncology Holdings, Inc. has a market capitalization of 26.47 million, with net sales of 0.00 million and a net profit of -130.02 million. The balance sheet shows shareholder's funds of 113.62 million and total assets of 147.78 million.

What does ALX Oncology Holdings, Inc. do?

22-Jun-2025

ALX Oncology Holdings, Inc. is a clinical-stage immuno-oncology company developing therapies targeting the CD47 checkpoint pathway to combat cancer. It has a market capitalization of $26.47 million and reported a net profit loss of $31 million as of March 2025.

Who are in the management team of ALX Oncology Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of ALX Oncology Holdings, Inc. includes Dr. Corey Goodman as Executive Chairman and Dr. Jaume Pons as President and CEO. The Board of Directors also features independent members Ms. Rekha Hemrajani, Mr. Jason Lettmann, Mr. Jack Nielsen, and Dr. Graham Walmsley.

Is ALX Oncology Holdings, Inc. overvalued or undervalued?

25-Jun-2025

As of May 17, 2021, ALX Oncology Holdings, Inc. is considered overvalued due to significant operational losses and negative return metrics, with a valuation grade that has shifted from risky to does not qualify, underperforming the S&P 500 with a year-to-date return of -72.47%.

Is ALX Oncology Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, ALX Oncology Holdings, Inc. is in a mildly bearish trend, influenced by daily moving averages, despite some bullish indicators, and has significantly underperformed the S&P 500 with a year-to-date return of -34.73%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Miscellaneous

Market cap

USD 59 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.04

Return on Equity

-176.04%

Price to Book

0.92

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-26 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

34.31%

6 Months

146.98%

1 Year

-11.61%

2 Years

-82.9%

3 Years

-87.93%

4 Years

-95.33%

5 Years

-98.12%

ALX Oncology Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is ALX Oncology Holdings, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for ALX Oncology Holdings, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend. While the weekly MACD and OBV are mildly bullish, the overall sentiment is tempered by the monthly Bollinger Bands showing bearishness and the KST indicating a bearish trend. The stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -34.73% versus the S&P 500's 12.22%, and a one-year return of -49.07% compared to 17.14% for the index....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-223.26%

EBIT to Interest (avg)

-92.37

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.97

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.35

EV to EBIT

0.40

EV to EBITDA

0.41

EV to Capital Employed

-22.96

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-147.26%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 35 Schemes (22.09%)

Foreign Institutions

Held by 61 Foreign Institutions (5.56%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 34.26% vs -15.20% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.30",
          "val2": "-41.30",
          "chgp": "43.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-25.90",
          "val2": "-39.40",
          "chgp": "34.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.17% vs -30.20% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-141.60",
          "val2": "-169.40",
          "chgp": "16.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.70",
          "val2": "1.60",
          "chgp": "6.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-134.80",
          "val2": "-160.80",
          "chgp": "16.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-23.30

-41.30

43.58%

Interest

0.40

Exceptional Items

-3.20

0.00

Consolidate Net Profit

-25.90

-39.40

34.26%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 34.26% vs -15.20% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-141.60

-169.40

16.41%

Interest

1.70

1.60

6.25%

Exceptional Items

0.00

Consolidate Net Profit

-134.80

-160.80

16.17%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 16.17% vs -30.20% in Dec 2023

All Annual Results

Company CV

About ALX Oncology Holdings, Inc.

ALX Oncology Holdings, Inc.

Miscellaneous

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on enabling patients to fight cancer by developing therapies that block the cluster of differentiation 47 (CD47) checkpoint pathway and bridge the innate and adaptive immune system. The Company is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, ALX148, is a CD47 blocking therapeutic. ALX148 is a fusion protein that combines a CD47 binding domain with its inactivated fragment crystallizable (Fc) domain. The CD47 binding domain of ALX148 is an affinity enhanced extracellular domain of signal regulatory protein alpha (SIRPa), a protein that is the natural receptor to CD47 found on myeloid cells. Its programs are focused on targeting CD47 across various oncology indications.

Company Coordinates

Company Details

866 Malcolm Road, Suite 100 , BURLINGAME CA : 94010

Tel: 1 650 4667125

http://alxoncology.com/

Registrar Details

ALX Oncology Holdings, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is ALX Oncology Holdings, Inc.?

Watch in Real-Time

What does ALX Oncology Holdings, Inc. do?

Who are in the management team of ALX Oncology Holdings, Inc.?

Is ALX Oncology Holdings, Inc. overvalued or undervalued?

Is ALX Oncology Holdings, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is ALX Oncology Holdings, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About ALX Oncology Holdings, Inc.

Company Coordinates